Q4 2022 Bioporto A/S Earnings Call Transcript
Greetings, and welcome to BioPorto Fourth Quarter and Full Year 2022 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Mr. Tony Pare. Thank you. You may begin.
/-
Thank you, Rob, and thank you to everyone joining us today for our Q4 and full year 2022 financial results and business update call. Joining me today is Neil Goldman, BioPorto's Executive Vice President and Chief Financial Officer.
Before we begin, let me remind you that the company's remarks made during this conference call today, March 30, 2023, may include predictions, estimates and other information that may be considered forward-looking. For your information, I refer to our public filings.
Let's proceed. 2022 has been a remarkable year of progress and achieved milestones for BioPorto. The most significant is the submission of our de novo application to the U.S. Food and Drug Administration or FDA,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |